Ibuprofen/oxycodone and Alcohol/Food Interactions
There are 2 alcohol/food/lifestyle interactions with ibuprofen / oxycodone.
Oxycodone Food
Major Food Interaction
GENERALLY AVOID: Alcohol may potentiate the central nervous system (CNS) depressant effects of opioid analgesics including oxycodone. Concomitant use may result in additive CNS depression and impairment of judgment, thinking, and psychomotor skills. In more severe cases, hypotension, respiratory depression, profound sedation, coma, or even death may occur.
GENERALLY AVOID: Grapefruit juice may increase the plasma concentrations of oxycodone. The proposed mechanism is inhibition of CYP450 3A4-mediated metabolism of oxycodone by certain compounds present in grapefruit, resulting in decreased formation of metabolites noroxycodone and noroxymorphone and increased formation of oxymorphone due to a presumed shifting of oxycodone metabolism towards the CYP450 2D6-mediated route. In 12 healthy, nonsmoking volunteers, administration of a single 10 mg oral dose of oxycodone hydrochloride on day 4 of a grapefruit juice treatment phase (200 mL three times a day for 5 days) increased mean oxycodone peak plasma concentration (Cmax), systemic exposure (AUC) and half-life by 48%, 67% and 17% (from 3.5 to 4.1 hours), respectively, compared to administration during an equivalent water treatment phase. Grapefruit juice also decreased the metabolite-to-parent AUC ratio of noroxycodone by 44% and that of noroxymorphone by 45%. In addition, oxymorphone Cmax and AUC increased by 32% and 56%, but the metabolite-to-parent AUC ratio remained unchanged. Pharmacodynamic changes were modest and only self-reported performance was significantly impaired after grapefruit juice. Analgesic effects were not affected.
MANAGEMENT: Patients should not consume alcoholic beverages or use drug products that contain alcohol during treatment with oxycodone. Any history of alcohol or illicit drug use should be considered when prescribing oxycodone, and therapy initiated at a lower dosage if necessary. Patients should be closely monitored for signs and symptoms of sedation, respiratory depression, and hypotension. Due to a high degree of interpatient variability with respect to grapefruit juice interactions, patients treated with oxycodone may also want to avoid or limit the consumption of grapefruit and grapefruit juice.
References (1)
- Nieminen TH, Hagelberg NM, Saari TI, et al. (2010) "Grapefruit juice enhances the exposure to oral oxycodone." Basic Clin Pharmacol Toxicol, 107, p. 782-8
Switch to consumer interaction data
Ibuprofen High Blood Pressure (Hypertension)
Major Potential Hazard, Moderate plausibility
NSAIDs - fluid retention
Fluid retention and edema have been reported in association with the use of nonsteroidal anti-inflammatory drugs (NSAIDs), including some topical formulations. NSAIDs (including topicals) can lead to new onset of hypertension or worsening of preexisting hypertension, either of which can contribute to the increased incidence of cardiovascular events. NSAIDs should be used with caution in patients with preexisting fluid retention, hypertension, or history of heart failure. NSAIDs should be avoided in patients with severe heart failure unless the benefits are expected to outweigh the risk of worsening heart failure; if an NSAID is used in such patients, they should be monitored for signs of worsening heart failure. Blood pressure and cardiovascular status should be monitored closely during the initiation of NSAID treatment and throughout the course of therapy.
References (20)
- (2002) "Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn
- (2002) "Product Information. Nalfon (fenoprofen)." Xspire Pharma
- (2002) "Product Information. Indocin (indomethacin)." Merck & Co., Inc
- (2002) "Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories
- (2002) "Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc
- (2006) "Product Information. Anaprox (naproxen)." Roche Laboratories
- (2001) "Product Information. Clinoril (sulindac)." Merck & Co., Inc
- (2001) "Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical
- (2001) "Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals
- (2001) "Product Information. Relafen (nabumetone)." SmithKline Beecham
- (2001) "Product Information. Dolobid (diflunisal)." Merck & Co., Inc
- (2001) "Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn
- (2001) "Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories
- (2001) "Product Information. Daypro (oxaprozin)." Searle
- (2001) "Product Information. Celebrex (celecoxib)." Searle
- (2001) "Product Information. Mobic (meloxicam)." Boehringer-Ingelheim
- (2012) "Product Information. Meclofenamate Sodium (meclofenamate)." Mylan Pharmaceuticals Inc
- (2016) "Product Information. Flector Patch (diclofenac topical)." Actavis U.S. (Alpharma USPD)
- (2022) "Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals Group, SUPPL-52
- (2025) "Product Information. Symbravo (meloxicam-rizatriptan)." Axsome Therapeutics, Inc.
Switch to consumer interaction data
Ibuprofen/oxycodone drug interactions
There are 882 drug interactions with ibuprofen / oxycodone.
Ibuprofen/oxycodone disease interactions
There are 27 disease interactions with ibuprofen / oxycodone which include:
- impaired GI motility
- infectious diarrhea
- prematurity
- asthma
- fluid retention
- GI toxicity
- rash
- renal toxicities
- thrombosis
- acute alcohol intoxication
- drug dependence
- hypotension
- intracranial pressure
- respiratory depression
- gastrointestinal obstruction
- PKU
- adrenal insufficiency
- liver disease
- renal dysfunction
- seizure disorders
- urinary retention
- anemia
- hepatotoxicity
- hyperkalemia
- platelet aggregation inhibition
- arrhythmias
- biliary tract disease
More about ibuprofen / oxycodone
- ibuprofen/oxycodone consumer information
- Check interactions
- Compare alternatives
- Reviews (1)
- Drug images
- Side effects
- Dosage information
- During pregnancy
- Drug class: narcotic analgesic combinations
Related treatment guides
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.